Table 3.
The characteristics of patients with NSCLC in two SES stage.
| Characteristic | SES-1 stage (%) | SES-2 stage (%) | P | |
|---|---|---|---|---|
| N | 20,237 | 20,141 | ||
| Age | 56.70 (6.50) | 56.38 (6.27) | <0.001* | |
| Race | White | 15,084 (74.5) | 15,122 (75.1) | <0.001* |
| Black | 2,402 (11.9) | 4,282 (21.3) | ||
| Other** | 2,751 (13.6) | 737 (3.7) | ||
| Sex | Female | 9,745 (48.2) | 8,807 (43.7) | <0.001* |
| Male | 10,492 (51.8) | 11,334 (56.3) | ||
| Histology | Adenocarcinoma | 14,404 (71.2) | 12,034 (59.7) | <0.001* |
| Squamous carcinoma | 3,728 (18.4) | 5,532 (27.5) | ||
| Large cell lung cancer | 401 (2.0) | 534 (2.7) | ||
| Other lung cancer | 1,704 (8.4) | 2,041 (10.1) | ||
| Site | Upper lobe | 11,135 (55.0) | 11,676 (58.0) | <0.001* |
| Middle lobe | 1,025 (5.1) | 905 (4.5) | ||
| Lower lobe | 5,363 (26.5) | 4,628 (23.0) | ||
| Main bronchus | 778 (3.8) | 1,046 (5.2) | ||
| Overlapping | 233 (1.2) | 241 (1.2) | ||
| Non-specified | 1,703 (8.4) | 1,645 (8.2) | ||
| Location | Right | 11,955 (59.1) | 11,878 (59.0) | 0.77 |
| Left | 8,050 (39.8) | 8,046 (39.9) | ||
| Bilateral | 232 (1.1) | 217 (1.1) | ||
| TNM.stage | IA | 2,948 (14.6) | 2,161 (10.7) | <0.001* |
| IB | 1,414 (7.0) | 1,275 (6.3) | ||
| IIA | 813 (4.0) | 849 (4.2) | ||
| IIB | 810 (4.0) | 867 (4.3) | ||
| IIIA | 2,672 (13.2) | 2,841 (14.1) | ||
| IIIB | 1,347 (6.7) | 1,577 (7.8) | ||
| IV | 10,233 (50.6) | 10,571 (52.5) | ||
| Surgery | No surgery | 13,458 (66.5) | 15,017 (74.6) | <0.001* |
| Surgery | 6,779 (33.5) | 5,124 (25.4) | ||
| Chemotherapy | 0 | 7,597 (37.5) | 8,349 (41.5) | <0.001* |
| 1 | 12,640 (62.5) | 11,792 (58.5) | ||
NSCLC, non-small cell lung cancer; SES, socioeconomic status.
*
Indicates significance of P < 0.05.
**
Indicates American Indian/AK Native, Asian/Pacific Islander and unknown.